SUSMED,Inc. (JP:4263)
:4263
Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥10.76B
Enterprise Value¥7.68B
Total Cash (Recent Filing)¥4.40B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.79
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-11.2
Revenue Forecast (FY)¥775.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and sizable equity materially reduce financial risk and provide flexibility to fund R&D, product rollout or strategic initiatives over the medium term. This durable capital buffer lengthens runway and lowers bankruptcy risk while the business pursues scaled revenue.
Exceptionally High Gross Margins (~97%)Very high gross margins reflect a scalable, software-like cost structure for digital health solutions; this structural advantage means incremental revenue can flow to the bottom line once fixed operating costs are controlled, supporting long-term margin expansion potential.
Resumption Of Revenue Growth And Digital-health PositioningA return to top-line growth, combined with a clear focus on clinical digital solutions, aligns the business with structural healthcare digitization. Sustainable revenue growth from clinical adoption supports recurring revenue potential and long-term market opportunity despite current scale limitations.
Bears Say
Deep, Persistent UnprofitabilityLarge and persistent operating losses materially weaken internal capital generation and lengthen the path to profitability. Over the medium term this constrains reinvestment, forces reliance on external funding, and creates execution risk if revenue scaling or cost discipline falters.
Worsening Cash Burn And Negative Operating FCFGrowing negative operating and free cash flow imply rising liquidity pressure and an increased need for financing or cash conservation. This structural cash burn can necessitate dilution, debt raises, or cutbacks that impair growth investments and strategic flexibility over the coming quarters.
Equity Erosion And Negative ROEDeclining equity despite no debt signals net asset depletion from losses, shrinking the financial cushion over time. Negative ROE reflects capital consumption rather than creation, raising solvency and investor-return concerns if the company cannot reverse losses and stabilize equity levels.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥570.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥10.76B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 60 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on May 08, 2026. The company reported -¥3.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.54.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥3.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.611%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED, Inc. is a Japanese company that specializes in creating and distributing medical treatment software. They focus on developing digital therapeutic applications delivered via smartphones, targeting various health conditions including insomnia, breast cancer, and kidney disease. Beyond these patient-facing tools, the company also provides a development platform for therapeutic applications and systems designed for managing clinical trials. Additionally, SUSMED offers expertise in medical data analysis and consulting services. The firm was established in 2015 and its primary operational base is located in Tokyo, Japan.